Professor Macek has been a member of the Expert Council since the beginning of the Association. We appreciate and thank him immensely for his service in the beginning of our activities. Now, Professor Macek’s work has taken him to a new role where we do not want to expose him to a conflict of interest, so we have agreed to terminate his membership of the Association.
“Professor, we appreciate your contribution to medicine, science and patients and we will continue to follow your work closely because you are a true expert in your field and a man in his place”, in the words of Radoslav Hajgajda, the founder of the Association.
prof. MUDr. Milan Macek, jr., Dr.Sc
Professor Milan Macek Jr. MD, DSc is the chairman of the Department of Biolog and Medical Genetics at the Charles University in Prague – the largest academic medical and molecular genetics institution in the Czech Republic, which also comprises a research and diagnostics reproductive genetics centre. He is also the past President of the European Society of Human Genetics (ESHG), board member of the European Society for Human Reproduction and Embryology and of the European Cystic Fibrosis Society (ECFS). His institute contributes to dissemination of knowledge in genetics gathered within various international European projects, such as CF Network, EuroGentest, EuroCareCF or Techgene, to Central and Eastern Europe.
Prof. Macek did his postdocs at the Institut of Human Genetics in Berlin and at the McKusick-Nathans Centre for Genetic Medicine, Johns Hopkins University in Baltimore. During that time he was also a fellow at Harvard School of Medicine in Boston. He hosted the 1995 HUGO Mutation Detection Course in Brno as well as the 2005 European Society of Human Genetics conference and of the 2008 European Cystic Fibrosis Conference, both held in Prague. Prof. Macek is national coordinator of Orphanet, active member of Eurogentest, has been the chief advisor of the Czech EU Council Presidency under which the “EU Council recommendation on an action in the field of rare diseases“was adopted in June 2009. He also serves at the EUCERD committee on rare diseases and is involved in the rare disease-focused initiatives EURenOmics and RD-Action.
